...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Hepatocellular carcinoma responding to superselective transarterial chemoembolization: An issue of nodule dimension?
【24h】

Hepatocellular carcinoma responding to superselective transarterial chemoembolization: An issue of nodule dimension?

机译:肝细胞癌对超选择性经动脉化疗栓塞的反应:结节大小的问题?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To evaluate the per-nodule efficacy of superselective transarterial chemoembolization of hepatocellular carcinomas (HCCs). Materials and Methods: From 2006-2009, 271 cirrhotic patients with 635 nodules underwent a first superselective transarterial chemoembolization, repeated on demand after local recurrences (LR) or partial responses (PR). Complete response (CR), time to nodule progression (TTnP), and local recurrence rate (LRR), according to three size classes (≤2 cm, 2.1-5 cm, and>5 cm) were evaluated. Results: After the first superselective transarterial chemoembolization, the CR was 64%, sustained over time in 77%, higher in small (68%) and intermediate-size (64%) nodules than in large nodules (25%; P<.001). The LRR was 23%:20% in small, 27% in intermediate, and 67% in large HCCs (P<.05). The median TTnP of large HCCs was 4 months versus 7-9 months for small and intermediate HCCs. The second superselective transarterial chemoembolization achieved a higher CR (63% in LR, 52% in PR) than the third superselective transarterial chemoembolization (32%). Median TTnP after the second superselective transarterial chemoembolization for LR and PR (8 months and 6 months) was longer than after the third superselective transarterial chemoembolization (3.5 months). Nodules≤5 cm had a CR after the first superselective transarterial chemoembolization (66%) and the second superselective transarterial chemoembolization for LR (64%) or PR (55%) higher than after the third superselective transarterial chemoembolization (40%); nodules>5 cm had a CR of 25% after the first superselective transarterial chemoembolization, LR of 50% and PR of 25%, and after the second and third superselective transarterial chemoembolizations, PR of 0%. Conclusions: Effectiveness of superselective transarterial chemoembolization has a clear cutoff above and below 5-cm nodules, with better results in smaller nodules. In HCCs≤5 cm, the efficacy of the first and second superselective transarterial chemoembolizations performed for LR was higher than the second superselective transarterial chemoembolization for PR and the third superselective transarterial chemoembolization. For HCCs>5 cm, retreatment of PR is of little value, and the third cycle is ineffective.
机译:目的:评估肝细胞癌(HCC)超选择性经动脉化学栓塞术的根瘤疗效。材料与方法:从2006年至2009年,对271例具有635个结节的肝硬化患者进行了第一次超选择性经动脉化学栓塞,在局部复发(LR)或部分缓解(PR)后按需重复。根据三种尺寸类别(≤2cm,2.1-5 cm和> 5 cm)评估了完全缓解(CR),结节进展时间(TTnP)和局部复发率(LRR)。结果:在第一次超选择性经动脉血栓栓塞治疗后,CR为64%,随时间推移持续维持在77%,小结节(68%)和中等大小结节(64%)高于大结节(25%; P <.001) )。 LRR在小型HCC中为23%:20%,在中级为27%,在大型HCC中为67%(P <.05)。大型HCC的TTnP中位数为4个月,而中小型HCC为7-9个月。与第三次超选择性经动脉化学栓塞术(32%)相比,第二次超选择性经动脉化学栓塞术获得更高的CR(LR中为63%,PR为52%)。 LR和PR的第二次超选择性经动脉化学栓塞术后(8个月和6个月)的中位TTnP比第三次超选择性经动脉化学栓塞术后(3.5个月)更长。结节≤5cm的患者在第一次超选择性经动脉化学栓塞(66%)和第二次超选择性经动脉化学栓塞后的LR(64%)或PR(55%)高于第三次超选择性经动脉化学栓塞(40%);结节> 5 cm在第一次超选择性经动脉化学栓塞后,CR为25%,LR为50%,PR为25%,第二和第三次超选择性经动脉化学栓塞后,PR为0%。结论:超选择性经动脉化学栓塞术的有效性在5 cm结节以上和以下具有明确的界限,结节较小时效果更好。在≤5 cm的肝细胞癌中,对LR进行的第一和第二次超选择性经动脉化学栓塞的疗效高于对PR的第二次超选择性经动脉化学栓塞和第三次进行的超选择性经动脉化学栓塞。对于> 5 cm的HCC,再治疗PR的价值很小,并且第三个周期无效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号